# Association Between Wearable Sensor Data and Clinical Scores in Individuals with Early-stage Multiple System Atrophy

VANDERBILT TUNIVERSITY

MEDICAL CENTER

LEAH G. MANN <sup>1</sup>, JOSE CASADO <sup>2</sup>, RAM KINKER MISHRA <sup>2</sup>, ADONAY NUNES <sup>2</sup>, PAULA TRUJILLO DIAZ <sup>1</sup>, JESSIE IREGUI <sup>1</sup>, AMY WYNN <sup>1</sup>, CYNTHIA WONG <sup>3</sup>, DAVID STAMLER <sup>3</sup>, ASHKAN VAZIRI <sup>2</sup>, AND DANIEL O. CLAASSEN <sup>1</sup>

<sup>1</sup>Department of Neurology, Vanderbilt University Medical Center, <sup>2</sup>BioSensics LLC, 57 Chapel St, Newton, MA, USA, <sup>3</sup>Alterity Therapeutics, San Francisco, CA, USA

### INTRODUCTION

- \* Multiple system atrophy (MSA) is a progressive neurodegenerative disorder characterized by a combination of parkinsonism, autonomic dysfunction, cerebellar symptoms, and pyramidal signs<sup>1</sup>.
- $\clubsuit$  MSA features α-synuclein aggregates within neurons and oligodendrocytes in addition to degeneration of striatonigral and olivopontocerebellar systems<sup>2-3</sup>.
- The wide array of implicated brain regions and symptoms highlights the heterogeneity of MSA, in addition to the challenges associated with timely and definitive diagnosis.
- Conventional clinical measurements of symptomatology, severity, and progression of MSA lack continuous data and consequentially have a restricted temporal application.
- Recent advancements in digital at-home monitoring instruments have begun to overcome the disadvantages of more traditional clinic-based measurements.

## **METHODS**

- ❖ Participants (n = 18) in the bioMUSE Natural History Study with clinically probable MSA wore sensors for continuous monitoring of physical activity over 12 months.
- \* We determined the association between gold-standard clinical measures and sensorderived parameters of locomotion, posture, and postural transitions at baseline
- \* We developed machine learning models to investigate whether sensor-derived measures could predict scores and performance on clinical evaluations.

## RESULTS


- Total walking time was <u>negatively correlated</u> with tandem walk (rho=-0.705) and Timed Up and Go (TUG) (rho=-0.811)
- Total sedentary time was <u>positively correlated</u> with tandem walk (rho=0.626) and TUG (rho=0.597)
- There was a <u>negative association</u> between daily step count and walking episodes with tandem walk and TUG.
- Additionally, we identified <u>positive relationships</u> between average sit-to-stand and stand-to-sit durations with UMSARS-II (rho=0.722, 0.628), the motor section of NNIPPS-PPS (rho=0.690, 0.689), and TUG (rho=0.644, 0.596).
- Regression models established successful prediction of clinical scores, with TUG demonstrating the highest explained variance.


## **Demographic and Clinical Evaluation**

	All Patients (N=18)
Demographics	
Age (years)	$62.9 \pm 9.2$
Sex (M/F)	10/8
Ethnicity (% Caucasian)	94%
Race (% Not Hispanic or Latino)	100%
Handedness (R/L)	13/0
Clinical Characteristics	
UMSARS-I	$16.5 \pm 5.7$
UMSARS-II	$14.1 \pm 5.8$
NNIPPS-PPS	$55.2 \pm 21.3$
Tandem Walk	$2.3 \pm 0.9$
TUG	$29.7 \pm 26$


## **Model Performance**

	MSE	MAE	Explained Variance
UMSARS-I	27.05	4.27	0.35
UMSARS-II	21.35	3.74	0.46
UMSARS-II Gait	4.54	1.73	0.53
NNIPPS-PPS	379.43	15.99	0.47
Tandem Walk	0.78	0.71	0.38
TUG	163.78	8.97	0.55





## Sensor and clinical assessment correlations



## CONCLUSIONS

- Sensor-derived metrics, specifically those measuring walking and postural transitions, may increase our understanding of impairments associated with MSA.
- Our results contribute meaningfulness to digital outcomes in MSA, underlining potential benefits sensors could hold for these patients.

#### References

1. Gilman, S., Wenning, G. K., Low, P. A., Brooks, D. J., Mathias, C. J., Trojanowski, J. Q., Wood, N. W., Colosimo, C., Dürr, A., Fowler, C. J., Kaufmann, H., Klockgether, T., Lees, A., Poewe, W., Quinn, N., Revesz, T., Robertson, D., Sandroni, P., Seppi, K., & Vidailhet, M. (2008). Second consensus statement on the diagnosis of multiple system atrophy. Neurology, 71(9), 670–676. https://doi.org/10.1212/01.wnl.0000324625.00404.15

2. Spillantini, M. G., Crowther, R. A., Jakes, R., Cairns, N. J., Lantos, P. L., & Goedert, M. (1998). Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neuroscience letters, 251(3), 205–208. https://doi.org/10.1016/s0304-3940(98)00504-7

3. Wenning, G. K., Tison, F., Ben Shlomo, Y., Daniel, S. E., & Quinn, N. P. (1997). Multiple system atrophy: a review of 203 pathologically proven cases. Movement disorders official journal of the Movement Disorder Society, 12(2), 133–147. https://doi.org/10.1002/mds.870120203